StockData
Viridian Therapeutics, Inc.\DE logo

Viridian Therapeutics, Inc.\DE (VRDN) stock

VRDNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 4/30255% above fair value
$30.12+0.06 (+0.20%)

Close on Nov 18, 2026Market cap $3.41BP/E –Yield –

Viridian Therapeutics, Inc.\DE operating margin

Operating margin is operating income as a percentage of revenue.

Viridian Therapeutics, Inc.\DE's operating margin for the twelve months ending Jun 30, 2026 was -569.7%. For fiscal 2025 it was -512.9%, against -99018.2% the year before. The highest annual figure on record is -3.6% in fiscal 2013.

Annual operating margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 2025-512.9%+98505.3
FY2024Dec 31, 2024-99018.2%−17983.2
FY2023Dec 31, 2023-81035.0%−73455.8
FY2022Dec 31, 2022-7579.2%−4888.4
FY2021Dec 31, 2021-2690.8%+7821.6
FY2020Dec 31, 2020-10512.4%−9571.4
FY2019Dec 31, 2019-941.0%−546.5
FY2018Dec 31, 2018-394.5%+268.3
FY2017Dec 31, 2017-662.8%−174.2
FY2016Dec 31, 2016-488.6%−47.8
FY2015Dec 31, 2015-440.8%−334.9
FY2014Dec 31, 2014-105.9%−102.3
FY2013Dec 31, 2013-3.6%–

Quarterly operating margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q2 FY2026Jun 30, 2026-44460.6%+97895.4
Q1 FY2026Mar 31, 2026-82389.4%+47980.1
Q4 FY2025Dec 31, 2025-92991.7%+28497.2
Q3 FY2025Sep 30, 2025-56.7%+97013.1
Q2 FY2025Jun 30, 2025-142356.0%−42096.3
Q1 FY2025Mar 31, 2025-130369.4%−52734.7
Q4 FY2024Dec 31, 2024-121488.9%−22213.9
Q3 FY2024Sep 30, 2024-97069.8%−25925.3
Q2 FY2024Jun 30, 2024-100259.7%−17933.3
Q1 FY2024Mar 31, 2024-77634.7%−3682.7
Q4 FY2023Dec 31, 2023-99275.0%−52545.5
Q3 FY2023Sep 30, 2023-71144.4%−68652.0
Q2 FY2023Jun 30, 2023-82326.4%−70778.0
Q1 FY2023Mar 31, 2023-73952.0%−61966.4
Q4 FY2022Dec 31, 2022-46729.5%−33140.3
Q3 FY2022Sep 30, 2022-2492.5%+4302.7
Q2 FY2022Jun 30, 2022-11548.4%−9897.2
Q1 FY2022Mar 31, 2022-11985.6%−10709.6
Q4 FY2021Dec 31, 2021-13589.3%+154184.8
Q3 FY2021Sep 30, 2021-6795.2%−3001.1
Q2 FY2021Jun 30, 2021-1651.2%−685.3
Q1 FY2021Mar 31, 2021-1276.0%−131.6
Q4 FY2020Dec 31, 2020-167774.1%−166158.2
Q2 FY2020Jun 30, 2020-3794.0%−3438.4
Q1 FY2020Mar 31, 2020-965.9%+2188.9
Q4 FY2019Dec 31, 2019-1144.4%+1051.6
Q3 FY2019Sep 30, 2019-1615.8%−646.4
Q2 FY2019Jun 30, 2019-355.7%+50.4
Q1 FY2019Mar 31, 2019-3154.8%−3058.3
Q4 FY2018Dec 31, 2018-2196.0%−1663.0
Q3 FY2018Sep 30, 2018-969.4%−608.3
Q2 FY2018Jun 30, 2018-406.1%+617.6
Q1 FY2018Mar 31, 2018-96.6%+1405.4
Q4 FY2017Dec 31, 2017-533.1%+628.8
Q3 FY2017Sep 30, 2017-361.1%+75.0
Q2 FY2017Jun 30, 2017-1023.7%–
Q1 FY2017Mar 31, 2017-1501.9%–
Q4 FY2016Dec 31, 2016-1161.9%–
Q3 FY2016Sep 30, 2016-436.1%–

More Viridian Therapeutics, Inc.\DE figures

See a number that looks wrong?